(Reuters) – Drugmaker Johnson & Johnson (NYSE:) set aside $3.9 billion in litigation expenses in 2020, which it said was “primarily associated with talc-related reserves and certain settlements”.
The company faces 25,000 lawsuits by former users of its baby powder who say asbestos-laced talc in the product caused their cancers, it said in a securities filing https://johnsonandjohnson.gcs-web.com/static-files/e2a329b4-aeb6-438d-a449-f0e282cf8ee0 on Monday.
The figure is nearly double the $2.1 billion the company, based in New Brunswick (NYSE:), New Jersey, said in November it would set aside for talc verdicts.
Johnson & Johnson has faced intense scrutiny over the safety of its baby powder following a 2018 Reuters report https://www.reuters.com/investigates/special-report/johnsonandjohnson-cancer that found it knew for decades about asbestos in the talc.
Internal company records, trial testimony and other evidence show that from at least 1971 to the early 2000s, J&J’s raw talc and finished powders sometimes tested positive for small amounts of asbestos.
The drugmaker is appealing to the U.S. Supreme Court against an award of $2.12 billion in damages in Missouri to women who blamed their ovarian cancer on asbestos in its products.
In November, a New York state judge ordered the company to pay damages of $120 million to a Brooklyn couple, after the woman blamed her cancer on asbestos exposure from using its baby powder.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Need Your Help Today. Your $1 can change life.
If you registered an account, please enter your details below to login. If this is your first time, proceed to the donation form.